Actionable news
All posts from Actionable news

Biotech Beat: RXi Pharmaceuticals Corp (RXII), Zafgen Inc (ZFGN), Five Prime Therapeutics Inc (FPRX)


RXi Pharmaceuticals Corp

On October 15, 2015, RXi Pharmaceuticals Corp (NASDAQ:RXII) announced positive phase 2a results for its RXI-109 compound. The trial, known as RXI-109-1402, was comparing RXI-109 treated scars against scars that were revised by surgery — control group. To test out dosing though Rxi gave one cohort of patients 5 mg/cm of RXI-109 while another cohort received 10 mg/cm of RXI-109. One quick thing to note is that both cohorts had a control group to determine which one performed better.

The end results was that both the 5 mg/cm RXI-109 and 10 mg/cm RXI-109 performed better than control according to investigators and panelists. These investigators and panelists were given photos to determine whether RXI-109 performed better than control. These independent reviewers were asked if “Scar A” looked better “Scar B” looked better or “not different” at all. There were two different scales used.

The investigators used a Physician and Observer Scar Assessment Scale — POSAS — and panelists used a Visual Analogue Scale — VAS. In each of the different scales the observers more correctly identified RXI-109 scars as being better than the control group. In the final assessment all observers were given all photos to make a final conclusion on the efficacy of the RXI-109 compound in scarring.

The final conclusion by panelists and investigators was that Rxi-109 showed better scar improvement over the control group with a p-value of p < 0.001. That means that over 3 months RXI-109 proved to be statistically significant in treating scars. We believe that these results validate that the sd-rxRNA technology platform works and that the company should not...